What:
A prospective, randomized, double-blind, placebo-controlled Phase-3 study of vgx-3100x delivered intramuscularly followed by electroporation with Cellectra™ 5psp for the treatment of HPV-16 and/or HPV-18 related high grade squamous intraepithelial lesion (HSIL) of the cervix.
Who: Females 18 and older.
Duration: 88 Weeks